Parkinson’s disease is one of the most common neurodegenerative conditions worldwide. In Colombia, more than 220,000 people suffer from it, according to the Colombian Association of Neurology. In this context, medical cannabis has been found to provide benefits in minimizing associated symptoms, such as anxiety and psychosis, as the disease progresses. 

Researchers at the University of Louisville School of Medicine in Kentucky have identified that cannabidiol (CBD) has antioxidant and anti-inflammatory properties, making it a promising therapeutic target for Parkinson’s patients. These effects of CBD protect the patient against oxidation and inflammation, which are key factors in neuroprotection in this disease. In addition, it has been observed that higher levels of CBD improve the physiological activity of Parkinson’s-related basal nuclei, thus reducing symptoms as the disease progresses. 

Studies have also shown that medical cannabis can effectively reduce anxiety, psychosis, and REM sleep problems associated with Parkinson’s. Furthermore, neuromodulation, in which the endocannabinoid system (ECS) plays a crucial role, is a promising alternative to delay or limit abnormal movements in this disease. 

According to Alejandro Venegas, CEO and Founder of Tarkus Pharma Lab, a Colombian laboratory dedicated to the production of medical cannabis derivatives, “the boost of cannabidiol in the market comes at a time when society demands natural products that do not negatively impact the environment. Cannabis derivatives benefit many people by treating different pathologies and improving their quality of life without generating addictions or side effects”. 

In summary, CBD shows significant therapeutic potential in the development and symptoms of Parkinson’s disease, thanks to its neuromodulatory and neuroprotective actions. These advances in medical cannabis research bring hope to patients and promise to improve their quality of life.